<?xml version="1.0" encoding="UTF-8"?>
<p>Although in most cases EEEV results in a self-limiting illness, it can cause severe encephalitis with 30–75% mortality in humans, depending on age, and up to 90% in horses [
 <xref rid="B11-vaccines-08-00273" ref-type="bibr">11</xref>]. Symptoms include fever, vomiting, respiratory complications, and focal neurological symptoms. Death is rapid, within 3–5 days after infection, and 50–90% of survivors can have long-lasting neurological defects. EEEV was identified in 1933 as a separate virus from WEEV by serology [
 <xref rid="B13-vaccines-08-00273" ref-type="bibr">13</xref>]. At least 285 cases have been reported in the US alone since 1964 [
 <xref rid="B11-vaccines-08-00273" ref-type="bibr">11</xref>]; there is a cyclical pattern of reported cases in the USA, with a recent peak in 2019. Interestingly, there have been reports of EEEV and VEEV coinfections in humans and equines [
 <xref rid="B14-vaccines-08-00273" ref-type="bibr">14</xref>]. EEEV cases are most frequently reported in eastern North, South, and Central America.
</p>
